Physician profile
Ted Ling
NPI 1902121544
$2,192.94
in general payments reported to CMS, 2019-2025
23 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $145 · 2021: $182 · 2022: $269 · 2023: $721 · 2024: $94.85 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $334.96 | 2020-2025 | Prolaris |
| Amgen INC. | $249.76 | 2019-2020 | |
| Palette Life Sciences, INC. | $173.48 | 2023 | |
| Novocure INC. | $157.71 | 2022-2023 | Optune |
| Galvanize Therapeutics, INC | $157.55 | 2023 | Aliya System |
| Sumitomo Pharma America, INC. | $145.94 | 2023-2025 | Orgovyx |
| Janssen Biotech, INC. | $134.91 | 2019-2025 | Darzalex, Tecvayli, Carvykti |
| Genentech USA, INC. | $125.00 | 2019 | |
| Genzyme Corporation | $117.19 | 2019 | |
| Boston Scientific Corporation | $93.66 | 2023 | Ams 700 |
| Bayer Healthcare Pharmaceuticals INC. | $84.25 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $78.07 | 2019-2025 | Libtayo |
| Coherus Oncology, INC. | $75.00 | 2021 | |
| Elekta, INC. | $43.19 | 2021 | |
| Blue Earth Diagnostics | $39.69 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $38.73 | 2023-2024 | |
| Pfizer INC. | $27.17 | 2025 | |
| Monteris Medical Corporation | $26.10 | 2025 | Neuroblate |
| Siemens Medical Solutions USA, INC. | $21.89 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $20.30 | 2025 | Calquence |
| Recordati_rare_diseases_inc. | $20.17 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $14.17 | 2025 | |
| Telix Pharmaceuticals | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.